Find clinical trials for Lung Cancer in Aurora, CO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma

Cancer

Carcinoma

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck

Triple Negative Breast Cancer

Colorectal Cancer

Lung Cancer trials near Aurora, CO, USA:

Testing the Engaged Approach to Lung Cancer Screening

The goal of this study is to assess feasibility and acceptability of the Engaged Approach to Lung Cancer Screening (EA-LCS) in dive ...

Enrolling

Lung Cancer

Behavioral: Engaged Approach to Lung Cancer Screening

University of Colorado Denver (CU Denver)

Denver, Colorado, United States

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...

Enrolling

Lung Cancer

EGFR Mutation-Related Tumors

Drug: BG-60366

Phase 1

•

BeiGene

Denver, Colorado, United States and 38 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting

Lung Cancer

Drug: Itacitinib

Drug: Osimertinib

Phase 1, Phase 2

•

Incyte

Denver, Colorado, United States and 30 other locations

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Enrolling

HER2 Mutant Non-small Cell Lung Cancer

HER2-positive Metastatic Breast Cancer

Drug: ELVN-002

Drug: Trastuzumab emtansine

Phase 1

•

Enliven Therapeutics

Aurora, Colorado, United States and 38 other locations

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor...

Active, not recruiting

Stage IA Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer

Procedure: Therapeutic Conventional Surgery

Drug: Osimertinib

Phase 2

•

University of California San Francisco (UCSF)

Aurora, Colorado, United States and 2 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting

Non-Small Cell Lung Cancer Metastatic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Drug: Patritumab Deruxtecan (Fixed dose)

Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

•

Daiichi Sankyo

Aurora, Colorado, United States and 123 other locations

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Sunvozertinib

Phase 1, Phase 2

•

Dizal Pharma

Aurora, Colorado, United States and 123 other locations